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SUMMARY – The purpose of our study was to contribute to better understanding of cerebros-
pinal fluid (CSF) as a valuable biological material in the research of brain tumors within the “low 
T3 syndrome”, and to discuss the role of thyroid hormones in the central nervous system in subjects 
with severe cerebral lesions. We studied the levels of total triiodothyronine (tT3), total thyroxine 
(tT4), free triiodothyronine (fT3), free thyroxine (fT4), reverse triiodothyronine (rT3) and thyrotro-
pin (TSH) in serum, and fT3, fT4, rT3 and TSH levels in CSF of patients with brain tumor, and 
compared the results with control group. Study results indicated a statistically significantly higher 
level of rT3 in serum and CSF of brain tumor patients vs. control group (p<0.05). The rT3/fT3 ratio 
was highest in CSF and serum of brain tumor patients, yielding a statistically significant difference 
(p<0.05). These results could suggest higher permeability of the blood-brain barrier in brain tumor 
patients. We also assume that rT3, in the framework of “cerebral low T3 syndrome”, is also generated 
through local intracerebral conversion. Disruption of this process in severe cerebral lesion can lead 
to increased rT3 concentrations, i.e. development of the “low T3 syndrome”.
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Introduction
Determination of thyroid hormone concentrations 
in cerebrospinal fluid (CSF) is of great importance in 
the research of the interaction of thyroid hormones 
and development and function of the central nervous 
system (CNS). There are many researches on thyroid 
hormone concentrations in serum and CSF of pa-
tients with different neurologic disorders. However, 
little is known about this topic and the pathophysi-
ology of thyroid hormone levels in CSF of patients 
with brain tumor. CSF thyroid hormone concentra-
tions may indicate pathologic changes in the brain, 
even earlier and more significantly than serum levels1. 
In some somatic and psychiatric diseases, there is a 
decrease of total triiodothyronine (tT3) in serum (“low 
T3 syndrome”), accompanied by reverse triiodothyro-
nine (rT3) increase, which is considered as a severity 
indicator of a general non thyroid illness. Our aim 
was to contribute to better understanding of CSF as 
a valuable biological material in the study of cerebral 
tissue damage, and to discuss the pathophysiology of 
thyroid hormones in patients with brain tumors, con-
sidered as a prototype of severe cerebral lesion.
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Material and Methods
All patients were Caucasians of European ori-
gin, and prior to enrolment in the study an informed 
consent was signed by all subjects. The study was 
approved by the local Ethics Committee. Based on 
hormonal laboratory findings and neck ultrasonogra-
phy, subjects with known thyroid disorders or thyroid 
hormone supplementation were not included in our 
study. The brain tumor group consisted of ten pa-
tients and control group of seven subjects (volunteers) 
matched for age and sex. Brain tumor was diagnosed 
according to clinical features and standard diagnostic 
procedure. Histopathology reports confirmed 2 astro-
cytomas, 2 glioblastomas, 2 meningeomas, 1 glioma 
piloides, 1 oligodendroglioma, 1 tumor of 3rd ventricle 
and mesencephalon, and 1 glioma of the cerebellum. 
At the time of sample collection, patients with proven 
brain tumor were hospitalized because of headache, 
dizziness and confusion as the leading symptoms of 
the underlying disease. The levels of total triiodothy-
ronine (tT3), total thyroxine (tT4) and thyrotropin 
(TSH) were determined by radioimmunoassay, while 
concentrations of free triiodothyronine (fT3) and free 
thyroxine (fT4) were measured by fluorometric assay 
(Wallac Pharmacia Company, Turku, Finland). rT3 
concentration was determined by radioimmunoassay 
utilizing the commercial test of Biodata Company 
(Horsham, USA). Statistical analysis was done using 
the MedCalc® statistical software (MedCalc 9.3.9.0, 
Frank Schoonjans, Mariakerke, Belgium). P values 
<0.05 were considered statistically significant.
Results
All results are shown in Table 1 (median values). 
tT3 serum concentration was lower in patients with 
brain tumor (1.3 nmol/L) compared with control 
group (1.4 nmol/L). tT4 level was higher in patients 
with brain tumor (110 nmol/L) compared with con-
trol group (101 nmol/L). Serum fT3 concentration 
median in brain tumor patients was 5.7 pmol/L vs. 
5.8 pmol/L in control group. fT3 concentration was 
lower in CSF (1.3 pmol/L in brain tumor patients 
and 3.5 pmol/L in control group) (p<0.05) than in se-
rum in both groups. Serum fT4 was higher in brain 
tumor patients (16.9 pmol/L) vs. control group (15.5 
pmol/L). CSF concentration of fT4 was 6.6 pmol/L in 
brain tumor patients and 3.0 pmol/L in control group, 
yielding a statistically significant between-group dif-
ference (p<0.05). The levels of serum TSH were lower 
in brain tumor patients (1.0 mIU/L) vs. control group 
(1.1 mIU/L), while TSH concentration in CSF was 
similar in the two groups (0.04 mIU/L in brain tumor 
patients and 0.10 mIU/L in control group). 
Our study indicated a statistically significantly 
higher level of rT3 in serum and CSF in brain tumor 
patients vs. control group (p<0.05). rT3 serum concen-
tration was 0.26 nmol/L in control group and 0.39 
nmol/L (p<0.05) in brain tumor patients. Median 
CSF concentration was 0.19 nmol/L in control group 
and 0.29 nmol/L (p<0.05) in brain tumor patients. 
The rT3/fT3 ratio was highest in CSF and serum of 
brain tumor patients, the difference being statistically 
significant. Median ratio was 6.9 in serum of brain 
Table 1. Serum (S) and cerebrospinal fluid (CSF) concentrations (median values) of total T3 (tT3), total T4 (tT4), free T3 
(fT3), free T4 (fT4), thyrotropin (TSH), reverse T3 (rT3) and rT3/fT3 ratio (rT3/fT3) in the group of patients with brain 














S 1.3 110 5.7 16.9 1.0 0.39 (p<0.05)  6.9 (p<0.05)
CSF  /  / 1.3  6.6 0.04 0.29 (p<0.05) 15.1 (p<0.05)
C
S 1.4 101 5.8 15.5 1.1 0.26  1.1
CSF  /  / 3.5  3.0 0.1 0.19  3.4
p for Hardy-Weinberg equilibrium, χ2-test
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tumor patients and 1.1 in control group. CSF me-
dian was 15.1 in brain tumor patients vs. 3.4 in con-
trol group (p<0.05). When patients were divided into 
three categories of improvement, fatal outcome and 
unknown, we found no correlation of serum and CSF 
rT3 concentration and rT3/fT3 ratio with short-term 
outcome of the disease (data not shown).
Discussion
The “low T3 syndrome” indicates alteration in thy-
roid hormonal status in clinically euthyroid patients 
with severe non-thyroid diseases. These changes 
include a T3 decrease and rT3 increase2. TSH level 
usually remains normal, but may decrease in severe 
non-thyroid disorders3,4. The etiology of “low T3 syn-
drome” is not completely clarified and the common 
factor still remains unclear. Activity defect of 5’-deo-
dinase type I causes reduced peripheral conversions of 
T4 into T3 and rT3 clearance with consecutively low T3 
level and high rT3 level. Some studies predicate that 
cytokines like tumor necrosis factor play an important 
role5. The “low T3 syndrome” is not only a second-
ary adaptation to catabolic state or caloric depriva-
tion as it was believed6,7, and is more likely actively 
induced by the disorder from the very beginning in 
order to prevent extensive catabolism. Transition of 
thyroid hormones into CSF and their important role 
in the development, function and nutrition of the 
CNS have long been a well known fact8,9. It is also 
common knowledge that function of CNS becomes 
significantly impaired in thyroid disorders, especially 
in myxedema coma and thyrotoxic crisis. Alterations 
in thyroid hormone levels in neurologic patients were 
used as an explanation for some CNS function disor-
ders, which can also appear as symptoms in patients 
with brain tumor10-12. Thompson et al.13 investigated 
subjects with various neurologic disorders and dem-
onstrated that rT3 levels were also lower in CSF than 
in serum, similar to the results of the present study. 
They also found a lower level of fT4 in CSF than in 
serum, which is consistent with our findings, contrary 
to some other authors who report higher levels of free 
thyroid hormones in CSF than in serum14. The lev-
els of TSH obtained in this study also correspond to 
the results reported by Thompson et al.13. The study 
by Nishikawa et al. included patients with meningi-
tis and acute cerebrovascular accident15. They found 
higher levels of rT3 and lower levels of fT3 in CSF 
than in serum, which is consistent with our findings. 
The group of patients with amyotrophic lateral scle-
rosis also showed higher levels of rT3 in CSF16. Sam-
paolo et al. report an increased CSF level of 3,3’,5’-tri-
iodothyronine in patients with Alzheimer’s disease17. 
It appears that some hormone aberrations in stroke 
are connected to cognitive dysfunction in the early 
post-stroke phases18,19. Spatial disorientation was con-
nected with low TSH level response to thyrotropin-
releasing hormone (TRH)10. Low response of TSH to 
TRH was also established in Alzheimer’s and depres-
sive disorders11,12. It is uncertain whether the secretion 
of these hormones has a direct impact on mental con-
dition, or there is a common suprapituitary mecha-
nism which affects pituitary and cognitive functions 
in the early post-stroke phases. Favorable influence of 
thyroid hormones, together with conventional antide-
pressant therapy is well known20. This can be related 
to the established thyroid hormone concentration re-
ported in depressive disorders21. Kirkegaard and Faber 
found depression convalescence to be accompanied by 
a decrease of rT3 levels in CSF21. In normal physi-
ological conditions, electrolytes and small molecules 
are transported through the blood-brain barrier easily, 
while the presence of macromolecules in the CSF is 
much lower. The higher levels of different chemical 
compounds in the CSF indicate their active concen-
tration in the cells (due to the increased demand for 
neural tissue metabolism) or their cerebral origin (e.g., 
neurotransmitters). Various pathologic conditions 
(e.g., compressive processes) may result in dysfunction 
of the blood-brain barrier, characterized by higher 
vascular permeability. At least three different deo-
dinases of iodothyronine contribute to preservation 
of intracellular level of T3 and modulate the biologi-
cal activity of thyroid hormones6. Most information 
about iodothyronine metabolism of the brain were 
obtained in rat research5,22,23 and recent studies on T4 
5-deodinases in human brain tumors indicated that 
human gliomas24, and probably also malignant skin 
lymphoma, support T4 5-deodinases activity. In our 
findings, the rT3/fT3 ratio was highest in brain tumor 
patients and also higher in CSF than in serum. These 
results, together with previously cited notions on T4 
5-deodinases activity in the brain, could indicate rT3 
local production in brain tissue, and the importance of 
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CSF which more explicitly reveals changes within the 
“low T3 syndrome” in serious neurologic conditions. 
Ultimately, the thyroid hormones probably cross the 
blood-brain barrier up to a certain level; however, we 
assume that rT3, in the framework of the „cerebral 
low T3 syndrome“25, is also generated through local 
intracerebral conversion. Disruption of this process in 
severe cerebral lesion can lead to increased rT3 concen-
trations, i.e. development of the “low T3 syndrome”. 
Because the present study had a relatively small num-
ber of patients, we have only presented our prelimi-
nary results. Therefore, our assumptions and results 
need to be further evaluated.
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Sažetak
TUMOR MOZGA KAO PROTOTIP TEŠKOG MOŽDANOG OŠTEĆENJA U BOLESNIKA SA 
“SINDROMOM NISKOG T3”
M. Solter, D. Katalinić, V. Vargek-Solter, K. Dobrović, A. Marić, Lj. Posavec, D. Solter i S. Pleština
Cilj studije bio je doprinijeti boljem poznavanju cerebrospinalne tekućine kao vrijednog biološkog materijala u istraži-
vanju moždanih tumora i “sindroma niskog T3”, te razmotriti ulogu hormona štitnjače unutar središnjega živčanog sustava 
kod bolesnika s ozbiljnim moždanim oštećenjem. Analizirali smo razinu ukupnog trijodtironina (tT3), ukupnog tiroksina 
(tT4), slobodnog trijodtironina (fT3), slobodnog tiroksina (fT4), reverznog trijodtironina (rT3) i tireotropina (TSH) u seru-
mu i razinu fT3, fT4, rT3 i TSH u cerebrospinalnoj tekućini u bolesnika s tumorom mozga te dobivene rezultate usporedili 
s kontrolnom skupinom ispitanika. Rezultati su ukazali na statistički značajno veću razinu rT3 u serumu i cerebrospinalnoj 
tekućini u bolesnika s tumorom mozga u usporedbi s kontrolnom skupinom (p<0,05). Odnos rT3/fT3 bio je također stati-
stički značajno veći kod bolesnika s tumorom mozga (p<0,05). Naše istraživanje moglo bi ukazivati na veću propustljivost 
krvno-moždane barijere u bolesnika s tumorom mozga. Također pretpostavljamo da se u bolesnika s tumorom mozga rT3 
pojačano stvara kroz aktivniju intracerebralnu pretvorbu. Svakako, naši rezultati trebaju biti potvrđeni i daljnjim podrob-
nijim istraživanjima.
Ključne riječi: Tumor mozga; Cerebrospinalna tekućina; Sindrom niskog T3; Hormoni štitnjače

